| | Latest News | Sarepta and Catalent Expand Strategic Manufacturing Partnership with Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate |
|
| Catalent signs an agreement to manufacture Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy (DMD). “Our partnership with the Sarepta team spans nearly a decade across multiple programs and modalities, and we look forward to working |
|
| together to manufacture these potentially life-changing and life-saving products for patients diagnosed with DMD and LGMD,” said Alessandro Maselli, Catalent’s President and Chief Executive Officer. |
|
| | Read the article | Catalent to Expand Its Biologics Analytical Services with New Facility in Durham, North Carolina |
|
| Catalent will establish an 80,000 square-foot biologics analytical center of excellence by fitting out an existing laboratory at a new site in Durham, within North Carolina’s Research Triangle.When complete it will provide comprehensive solutions that include bioassays, physico-chemical testing, and as well as process validation support, stability testing, in-process manufacturing and formulation analysis, and post-packaging identification“. |
|
| | | Catalent in the News | Stable, Site-Specific Antibody-Drug Conjugation with SMARTag® Technology and Innovative Linker |
|
| In a recent ADC REVIEW article, Penelope Drake, Ph.D , Head of R&D, Bioconjugates at Catalent, shares her thoughts on how Catalent’s award winning SMARTag ADC technology overcomes the limitations associated with conventional protein chemistries that produce heterogeneous |
|
| products with variable conjugate potency, toxicity, and stability. The technology was conceived in Carolyn Bertozzi’s laboratory as part of the suite of bioorthogonal chemistry innovations that earned her the 2022 Nobel Prize in Chemistry. | | Read the article |
|
| Biopharmaceuticals and Biosimilars | Catalent's Stacey Treichler, Ph.D., Director, Head of Marketing & Strategy, BioModalities joined industry experts in American Pharmaceutical Review's Biopharmaceuticals and Biosimilars roundtable. "I believe we will see more complexity in the types of #biologics that are being developed. Multi-specific antibodies, antibody-drug conjugates, and antibody fusions are just some examples of complex proteins that I believe will continue to take a larger share of the biologics pipeline." added Stacey Treichler when commenting about biopharmaceutical segment of the industry heading in the next five years. |
|
| | | Catalent Opens Doors at Belgium Cell Therapy Plant |
|
| The contract manufacturing major Catalent has completed and opened a commercial-scale facility in Gosselies, Belgium, adding 60,000 square feet of dedicated space for autologous and allogeneic cell therapy manufacturing through to late-stage clinical and commercial-scale supply. |
|
| | | Catalent for Biotech Consultants | Are you searching for the latest technological solutions for your partners?
We scale our approach according to what our customers need for their program to be a success. Catalent recognizes and supports the consultant’s key role, helping our partners to stay in tune with the latest advancements, technologies and solutions available. |
|
| | Learn More | Webinar: Aligning Clinical Supply Strategy with the Target Product Profile for your Clients
The COVID-19 pandemic has permanently changed pharmaceutical development. As a result, there is a greater focus on the supply chain perspectives with respect to how new drugs are developed. The Target Product Profile (TPP) is key to new drug success, specifically in anticipating and providing an approach to mitigate challenges. Aligning key aspects of clinical supply early in the TPP build is critical. From this webinar, you will learn the framework to provide a strong TPP and risk management structure. | | Watch Now |
|
| Upcoming Events: Join Our Experts to Hear the Latest on Technology Development Programs |
|
| Biologics
Advanced Therapies Week 2023 |Miami, FL | January 17-20, 2023 Join Catalent’s cell and gene therapy expert, George Buchman Ph.D., VP, Pre-Clinical and Process Development, Catalent Cell and Gene Therapy, as he presents UpTempo Virtuoso™ AAV Platform Process for AAV viral vector development and GMP production. Schedule a meeting
CASSS WCBP 2023 | Washington, DC | January 24-26, 2023 Join Dr. Wai Lam Ling, VP Advisory at Catalent on January 25 as she will present insights on the current bioanalytical landscape, its challenges, and strategies to accelerate biologics development. In addition, plan to visit our Catalent Biologics experts in booth 20 or schedule a meeting to learn more. Schedule a meeting
2nd Annual mRNA-Based Therapeutics Summit Europe | Berlin, Germany | January 24-26, 2023 Join Nuria Gomez Santos, Ph.D., Head of Process & Analytical Development, pDNA, Catalent as she presents her thoughts about the competitive landscape of emerging biomodalities for cost-effective solutions for plasmid DNA (pDNA). Schedule a meeting
2nd Allogeneic Cell Therapies Summit Europe | London, UK | January 30-February 1, 2023
Stop by the booth or schedule a meeting with the Catalent Cell & Gene Therapy expert and learn more about the path of commercialization for allogeneic cell therapies.
Webinar | Development of Orphan Biologics: Challenges and Opportunities | February 21, 2023 The development of therapies for rare diseases comes with distinct challenges such as patient recruitment, and difficulties in setting meaningful clinical endpoints, as well as manufacturing and supply challenges. In this webinar, speakers will cover aspects of clinical trial design for orphan biologic products as well as key strategies for ensuring appropriate clinical trial supply throughout clinical development. Register now |
|
| Pharmaceuticals and Consumer Health
Formulating the Future: Accelerating Oral Drug Development & Manufacturing | London, UK | January 19 Join this workshop to network with our industry leaders and learn more about our drug development and manufacturing technologies and discover how you could accelerate progression to the clinic and on-to-market success. Register now
Webinar| Small Molecule Orphan Drugs: Status Quo, Challenges, and Perspectives | February 7, 2023 Join this webinar to learn more about the key drivers that motivate drug sponsors in developing orphan drugs. In addition, experts will explore the challenges of orphan drug development and manufacturing and will discuss how the industry is leveraging strategic partnerships to help mitigate these challenges to create a viable orphan drug business model. Register now
Webinar | Tackling Bioavailability Challenges for the Next Generation of Small Molecules | February 16, 2023 Join this webinar to hear industry experts share insights into small molecule drug development advancements and discuss innovative, scalable drug delivery technologies proven to address the industry’s growing need for improving solubility and enhancing bioavailability. Register now
Targeted Protein Degradation Summit Europe |London, UK | March 28-30, 2023 Join Steven Winling, Scientific Advisor, Science & Technology, as he discusses Catalent’s tailored developability assessment for bifunctional protein degraders, which can help predict viable formulation and drug delivery strategies for lead drug candidates to reach their true potential. Schedule a meeting |
|
|
|
A Catalyst in Drug Development |
|
| Mubashar Chughtai Associate Senior Scientist |
|
| As an active member of Catalent’s scientific research community Mubashar Chughtai has over 10 years of experience as a Bioinorganic Chemist. Having developed several cleaning validation methods for active pharmaceutical ingredient, detergent, and allergen trace residuals on manufacturing surfaces Mubashar is also heavily involved in method validations and verifications |
|
| and has worked on the transfer of complex residual solvents including USP<467> methods. Mubashar resides in the Windsor Ontario location, and thrives on meeting challenges head on and facing them with sound scientific principles. Get to know this Catalyst in Drug Development today.
You can access their works here. | Featured works: | Webinar: Omega-3 Fatty Acids-Quality Delivery of Innovative Dose Forms |
|
| Omega-3 fatty acids are essential nutrients that support overall health, however dosage form is the key for consumer acceptance and compliance. This webinar will present a range of innovative dosage forms specifically designed to overcome Omega-3 challenges such as fish burps, taste and odor masking, vegetarian alternatives etc. |
|
| | |
|
Biologics Video: “ Choosing a CDMO Partner for Your Late-Stage and Commercial Biologics Programs” Watch this fireside chat with Pharmaceutical Technology and Stacey Treichler, Ph.D., Director, Head of Marketing & Strategy, BioModalities, Catalent Biologics, and learn more about the considerations for choosing the right CDMO for your late stage biotherapeutics programs in this interview.
Webinar: “ Plasmid DNA and Advanced Therapies: Accelerating Path to Clinic” Gene therapies and emerging biomodalities are developing at an unprecedent pace and improving the lives of patients around the world. Join this webinar for an in-depth discussion of the challenges innovators of cell and gene therapies face and how experts resolve these barriers through adopting technologies and strategies that drive an optimized plasmid production process and its supply.
Videos: “ mRNA: A New Option for Vaccines and Therapeutics”, “ mRNA Development and Manufacturing – CMC challenges and Solutions”, and “ The Unique Challenges of Lipid Nanoparticle Development and Manufacturing” Breaking New Ground: Making mRNA into an Established Therapeutic Modality. Once one of the riskiest new technologies in drug R&D, the pandemic made mRNA a household topic of discussion. In addition to COVID-19, among the RNA-based therapeutics, mRNA have the potential to treat a variety of diseases. Catalent’s experts Wai Lam Ling, Ph.D., VP Scientific Advisory, and Jingtao Zhang, Ph.D., Scientific Director, shared their thoughts in this series of fireside chat interviews with Pharmaceutical Technology. |
|
| | | | | Biologics In this 360° virtual tour of our Anagni, Italy site, explore the world-class late-stage and commercial manufacturing for vial fill/finish and secondary packaging of biologics and sterile products. | Pharmaceuticals and Consumer Health In this 360° virtual tour let’s have a look at our Softgel manufacturing site located in Buenos Aires, Argentina. This facility supplies hundreds of Consumer Health & Pharma products to clients in Latin America, North America and Europe and provides to our partners’ the benefit of best-in-class standards. |
|
| We are the Catalyst for your success. Join us! |
|
| We are the Catalyst for your success. Join us! Catalent ignites the development of their future leaders by continuously investing in their employees and creating an innovative environment to advance their potential. We are hiring across sites in North America, Latin America, Europe and Asia Pacific.
Visit www.catalent.com/careers for more information. |
|
| | |
|
Every molecule has a challenge. We have a solution.
|
|
| | | or call +1 877 891 9609 to speak with one of our experts today! |
|
| | |
|
To unsubscribe or manage your subscriptions, please click here.
For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at sales@catalent.com, or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers.
Catalent Pharma Solutions respects your privacy.
Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement of the website, its owner(s) or the content.
© 2023, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved.
|
|
|
|
|
